SGLT2i exposure was associated with superior reduction in a composite of kidney outcomes compared to GLP1RA among patients with type 2 diabetes (P<0.01).
Cohort
Does SGLT2i reduce adverse kidney outcomes compared to GLP1RA in patients with type 2 diabetes?
In a real-world cohort of patients with type 2 diabetes, SGLT2 inhibitors may be superior to GLP-1 receptor agonists in reducing adverse kidney outcomes.
p-value: p=<0.01
Background: Kidney benefits have been demonstrated for both sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) compared with placebo in patients with type 2 diabetes. This study aimed to compare the impacts of SGLT2i and GLP1RA on the trend of estimated glomerular filtration rate (eGFR) and other kidney outcomes. Methods: Using a real-world population-based database, the Hong Kong Hospital Authority (HA) database, of patients with type 2 diabetes between January 2008 and December 2020, patients started on SGLT2i were compared with those started on GLP1RA, with one-to-one propensity-score matching. Primary outcome was a composite of sustained ≥50% eGFR decline, end-stage kidney disease (ESKD), incident macroalbuminuria and kidney-related mortality. Secondary outcome was the rate of eGFR decline. Findings: < 0·01). Interpretation: Our results suggest that SGLT2i might be superior to GLP1RA in reducing kidney outcomes among patients with type 2 diabetes. Future trials are needed to corroborate our findings. Funding: None.
Lui et al. (Sat,) conducted a cohort in Type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. Glucagon-like peptide-1 receptor agonists (GLP1RA) was evaluated on Composite of sustained ≥50% eGFR decline, end-stage kidney disease (ESKD), incident macroalbuminuria and kidney-related mortality (p=<0.01). SGLT2i exposure was associated with superior reduction in a composite of kidney outcomes compared to GLP1RA among patients with type 2 diabetes (P<0.01).